Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes fromFinra
Moving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
- MACD is crossing MACD signal line at 0.9. MACD crossing signal line is bullish signal.
|Earning Growth (QoQ)||57%|
|Revenue Growth (QoQ)|
|Held by Institutions %||91%|
|1 Day Vol Adjusted Return||0.2|
|1 Month Vol Adjusted Return||0.8|
|3 Month Vol Adjusted Return||-7.1|
|6 Month Vol Adjusted Return||-6.5|
|20 Days SMA Price ZScore||1.2|
|50 Days SMA Price ZScore||-0.4|
|12 -26 Days PPO||-1.3|
|1 Month Average Short Volume Ratio||42.8|
|1 Day Volume Change ZScore||-1.2|
|1 Month Daily Vol||2.4|
BATON ROUGE, La., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ: AMED), a leading provider of home health, hospice, personal care and high-acuity care, names Scott Ginn, Executive Vice President and Chief Financial Officer, its Acting Chief Operating Officer, effective immediately. “I am delighted to have Scott Ginn serving as a trusted partner in this critical role on our leadership team,” stated Paul Kusserow, Chairman and CEO of Amedisys. “Scott is well respected within Amedisys an
Here are the biggest management changes and dispatches from the past week, as first reported on InvestingPro+.
A publicly traded home health and hospice company is shaking up its C-suite. The company’s board of directors appointed Amedisys Chairman and former CEO Paul Kusserow as interim CEO until a permanent replacement is found. Kusserow previously worked as Amedisys’ CEO from 2014 until April, when Gerard was hired.
Investors need to pay close attention to Amedisys (AMED) stock based on the movements in the options market lately.
Today, the Board of Directors of Amedisys, Inc. (NASDAQ: AMED) announced a leadership change that President and Chief Executive Officer, Chris Gerard, will leave the company effective November 17, 2022, and Paul Kusserow, Chair of the Board of Directors will take over as Chief Executive Officer until a new Chief Executive Officer is identified.
Today, the Board of Directors of Amedisys, Inc. (NASDAQ: AMED) announced that President and Chief Executive Officer, Chris Gerard, will leave the company effective November 17, 2022.
Amedisys ( NASDAQ:AMED ) Third Quarter 2022 Results Key Financial Results Revenue: US$558.0m (flat on 3Q 2021). Net...
Today we will run through one way of estimating the intrinsic value of Amedisys, Inc. ( NASDAQ:AMED ) by projecting its...
BATON ROUGE, La., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ: AMED), a leading provider of quality home health, hospice, personal care and high-acuity care, issued the following statement following the CY 2023 Home Health Final Rule by the Centers for Medicare and Medicaid Services (CMS). “While not the ideal outcome, today’s release of the CY 2023 Home Health Final Rule is a welcomed improvement over what was proposed by CMS this summer in regard to the overall payment update for
Within Amedisys (AMED) Home Health and Hospice, the reinstatement of sequestration reduces growth in Q3.